Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

NCT04397770 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: SHR1210
DRUG: apatinib mesylate
DRUG: Temozolomide Injection

Sponsor

Peking University Cancer Hospital & Institute